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Markov model for evaluating the long-term cost-effectiveness of clopidogrel in
patients with NSTEMI was adapted and extended by using local utility and eco-
nomic values. The effect of clopidogrel was applied during the first year in the
model and was estimated by the CURE trial. Costs assigned to each health state
included antiplatelet treatment cost, cost for the management of adverse events
and the costs for concomitant medication, hospitalization, outpatient visits, reha-
bilitation and nursing. The incremental cost-effectiveness ratio (ICER) was calcu-
lated. A probabilistic sensitivity analysis was conducted in order to assess the
impact of all uncertain model parameters varying simultaneously. The results are
presented as mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed
a discounted survival of 8.27 (8.25-8.30) years in the aspirin treatment group and
8.42 (8.39-8.44) years in the aspirinclopidogrel treatment group; a difference of
0.14 (0.11-0.18, p0.001) years. Adjusting the survival for the quality of life, the
model predicts 7.52 (7.15–7.79) and 7.66 (7.27–7.94) discounted QALYs in the aspirin
and clopidogrelaspirin arm, respectively, resulting in a difference of 0.14 QALYs
(0.10-0.17, p0.001). The cumulative lifetime costs per patient were € 15,976
(€14,848–€17.156) and € 15,392 (€14,301- €16,535), for aspirin and
clopidogrelaspirin treatment arm, respectively, a difference of € 584 (€525-€647).
The ICER was €4111 (€3342–€5169) for each life-year saved and €4385 (€3487–€5647)
for each QALY saved. For a decision threshold of €5500 per discounted QALY,
clopidogrelaspirin is cost-effective in more than 95% of randomly sampled
analyses. CONCLUSIONS: Treatment with clopidogrel in addition to aspirin is a
cost-effective treatment option in patients with NSTEMI from the perspective of a
third-party payer in Greece.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran etexilate 150dib rel-
ative to Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treat-
ment, in the management of patients with Atrial Fibrillation in the Greek health
care setting. METHODS: A Markov model was adopted to estimate long term out-
comes of patients moving during their lifetime in between the following health
states: primary and recurrent ischemic stroke, hemorrhagic stroke, transient isch-
emic attack, systemic embolism, acute myocardial infarction, intracranial hemor-
rhage, extracranial hemorrhage and death. Data on event rates and patent quality
of life associated with different health states and patient survival times were based
on a multinational clinical trial (RE-LY) and the related literature. Furthermore,
data on resource use associated with the management of patients and of different
events were collected from a survey of local hospitals. Unit prices were collected
from official resources and relate to 2011. A 3.5% discount rate was used for all
outcomes. Sensitivity analysis and probabilistic analysis was used to test the ro-
bustness of the analysis RESULTS: The mean total life-time cost of patients on
Dabigatran etexilate was estimated at €20,103, relative to €11,639 in the case of
Sintrom, while mean Quality Adjusted Life Years (QALYs) were 9.86 and 9.83 for the
two treatments, respectively. The incremental cost-effectiveness ratio of Dabiga-
tran etexilate relative to Sintrom was estimated at €25,952. Similarly it was esti-
mated at €8,223, €10,392 and €7,536 against Asprin-Clopidogrel, Aspirin alone and
No-Tretament, respectively. Sensitivity analyses indicated that the cost-effective-
ness of Dabigatran etexilate remained below acceptable thresholds (€50,000 per
QALY gained) in significant variations of baseline parameters. Probabilistic analy-
sis indicated that in about 85% of cases its cost-effectiveness ratios, relative to the
above comparators were below the aforementioned threshold. CONCLUSIONS:
Dabigatran etexilate may represent a cost-effective choice for the management of
patients with atrial fibrillation in Greece.
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OBJECTIVES: To conduct an economic analysis comparing treatment with clopi-
dogrel against aspirin in patients with peripheral artery disease, a recent stroke, or
a recent myocardial infarction from the Greek third-party-payer perspective.
METHODS: A Markov model with a 6-month cycle length was developed to evalu-
ate the lifetime cost-effectiveness of clopidogrel versus aspirin. The effect of clopi-
dogrel was applied only during the first 2 years of the model and this was retrieved
from CAPRIE trial. Local utility data were used to estimate quality-adjusted life
years (QALY). The state-specific costs consists of the costs that reflect and encap-
sulate all resource used for the care of patients within the health care system
during a 6-month period in the acute and follow-up phase, separately. The cost-
effectiveness of clopidogrel over aspirin was evaluated by calculating the incre-
mental cost per life year saved (LYS) and incremental cost per QALY saved (ICER). A
probabilistic sensitivity analysis was conducted and the results are presented as
mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed that the dis-
counted survival was 11.83 (11.41-12.22) years and 12.17 (11.75-12.55) years in as-
pirin and clopidogrel treatment group, respectively, a difference of 0.27 (0.10-0.45)
life-years. The corresponding discounted QALYs were 8.63 (8.34 – 8.91) and 8.84
(8.54–9.10), respectively. The cumulative lifetime costs per patient were €19,880
(€18,863–€20,939) and €21,039 (€20,006–€22,089), for aspirin and clopidogrel treat-
ment arm, respectively. The ICER was calculated to be € 4,921 (€ 3,079–€ 9,969) for
each LYS and €6,326 (€ 3,737–€ 16,699) for each QALY saved. For a “willigness-to-
pay” threshold of € 9,500 per discounted QALY, clopidogrel was found to be cost-
effective in more than 90% of randomly sampled analyses. CONCLUSIONS: This
economic analysis indicates that treatment with clopidogrel for secondary preven-
tion of cardiovascular events in atherothrombotic patients is a cost-effective anti-
platelet treatment over aspirin in a Greek third-party payer perspective.
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OBJECTIVES: To evaluate common therapeutic alternatives (rosuvastatin, atorvas-
tatin, simvastatin, pravastatin) for the prevention of primary and secondary car-
diovascular events in Greece. METHODS: A Markov model with distinct health
states (no event, fatal/non fatal acute myocardial infarction (MI), fatal/non fatal
stroke, post-MI, post-stroke & all cause death) was developed, to reflect within a
20-year time span health and economic outcomes of non-smoking patients as-
sumed to be at base line at mean age of 70 years, with no prior treatment of
hypertension, systolic blood pressure at 140mmHg and total cholesterol at 260mg/
Dl. The HellenicSCORE risk score equation was used to transform systolic blood
pressure reductions in different medications into long-term reductions in cardio-
vascular events. Transition probabilities from acute myocardial infarction or
stroke to death were obtained from the Framingham study. Treatment cost was
estimated from a payer perspective and includes the cost of medication and all
resources used in the management of events. Health states were associated with
local quality of life data to estimate Quality Adjusted Life Years (QALYs). A proba-
bilistic sensitivity analysis was conducted to deal with uncertainty. Prices reflect
2011 and outcomes were discounted at 3.5%. RESULTS: For males, discounted
QALYs were: 10.18 (95%CI:10.11-10.23), 10.04 (95%CI:9.96-10.10), 9.94 (95%CI: 9.84-
10.02) and 9.88 (95%CI: 9.76-9.97) for rosuvastatin, atorvastatin, simvastatin and
pravastatin, respectively. The mean total cost was: 15,646 (95%CI:15,173-16,130),
16,678 (95%CI:16,184-17,187), 17,242 (95%CI:16,732-17,766) and 17,585 (95%CI:
17,060-18,119) respectively. For females, QALYs were: 10.33 (95%CI:10.28-10.37),
10.26 (95%CI:10.20-10.30), 10.20 (95%CI:10.13-10.25) and 10.16 (95%CI: 10.08-10.22),
respectively. Similarly, mean total cost was: 15,030 (95%CI:14,632-15,430), 15,608
(95%CI:15,192-16,023), 15,951 (95%CI:15,521-16,379) and 16,153 (95%CI:15,714-
16,591) respectively. Hence rosuvastatin was a dominant therapy option.
CONCLUSIONS: Rosuvastatin may represent an attractive option relative to alter-
native therapies, from an economic and clinical point of view, in the primary and
secondary prevention of cardiovascular events in the National Health Service of
Greece.
PCV80
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OBJECTIVES: The cost-effectiveness study of pravastatin for primary prevention of
coronary artery disease (CAD) was assessed applying epidemiologic data and risk
predictions of CAD in Japan. METHODS: A Markov transition model was used for
evaluating the cost-effectiveness of 20mg/day of pravastatin treatment with diet
therapy. The incidence of acute myocardial infarction (AMI) was estimated using
newly developed risk predictions of CAD in Japan. Hypothetical population of men
and women from 45 to 75 years old were assumed according to the cardiac risk
factors from Japan Atherosclerosis Society Guideline for Prevention of Atheroscle-
rotic Cardiovascular Disease. Quality-adjusted life-years (QALYs) and incremental
cost-effectiveness ratios (ICERs) over a lifetime horizon were estimated from the
perspective of payers. One way sensitivity analysis and probabilistic sensitivity
analysis were conducted to see the robustness of the model. RESULTS: The pre-
dicted incidence of AMI was 4.4/10,000 person-years for men and 1.4/10,000 per-
son-years for women aged 55 years with initial total cholesterol level (TC) of 240
mg/dl without other cardiac risk factors (i.e. low cardiac risk) and 20.1/10,000 per-
son-years for men and 6.6/10,000 person-years for women with initial TC level of
240 mg/dl, and risks of smoking, hypertension and diabetes (i.e. high cardiac risk).
Over a lifetime horizon, the ICERs were depended on the level of cardiac risk fac-
tors. The ICERs were decreased proportionally with increased age and number of
cardiac risk factors. Considering the willingness to pay threshold per QALYs, prav-
astatin treatment was not cost-effective in all subgroups evaluated in this study.
CONCLUSIONS: Due to the predicted low incidence of CAD in Japan, pravastatin
treatment was not cost-effective for primary prevention of CAD in population not
only at low cardiac risk but also at high cardiac risk. Further evaluations of cost-
effectiveness on CAD treatment in Japan using available epidemiological data and
risk predictions are needed.
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